|
1
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ,
Dobelbower M, et al: Non-small cell lung cancer, version 5.2017,
NCCN clinical practice guidelines in oncology. J Natl Compr Canc
Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Olaussen KA and Postel-Vinay S: Predictors
of chemotherapy efficacy in non-small-cell lung cancer: A
challenging landscape. Ann Oncol. 27:2004–2016. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reguart N, Cardona AF, Carrasco E, Gomez
P, Taron M and Rosell R: BRCA1: A new genomic marker for
non-small-cell lung cancer. Clin Lung Cancer. 9:331–339. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ricciuti B, Leonardi GC, Metro G, Grignani
F, Paglialunga L, Bellezza G, Baglivo S, Mencaroni C, Baldi A,
Zicari D and Crinò L: Targeting the KRAS variant for treatment of
non-small cell lung cancer: Potential therapeutic applications.
Expert Rev Respir Med. 10:53–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Y, Fang W, Yan Y, Wang M, Kang S,
Sheng J, Zhan J, Chen N, Hong S, Yang Y, et al: The efficacy of
first-line chemotherapy is associated with KRAS mutation status in
patients with advanced non-small cell lung cancer: A meta-analysis.
Med Oncol. 32:612015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pan W, Yang Y, Zhu H, Zhang Y, Zhou R and
Sun X: KRAS mutation is a weak, but valid predictor for poor
prognosis and treatment outcomes in NSCLC: A meta-analysis of 41
studies. Oncotarget. 7:8373–8388. 2016.PubMed/NCBI
|
|
7
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maus MK, Mack PC, Astrow SH, Stephens CL,
Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, et al:
Histology-related associations of ERCC1, RRM1 and TS biomarkers in
patients with non-small-cell lung cancer: Implications for therapy.
J Thorac Oncol. 8:582–586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Metro G, Chiari R, Bennati C, Cenci M,
Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini
V, et al: Clinical outcome with platinum-based chemotherapy in
patients with advanced nonsquamous EGFR wild-type non-small-cell
lung cancer segregated according to KRAS mutation status. Clin Lung
Cancer. 15:86–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marabese M, Ganzinelli M, Garassino MC,
Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella
C, Floriani I, et al: KRAS mutations affect prognosis of
non-small-cell lung cancer patients treated with first-line
platinum containing chemotherapy. Oncotarget. 6:34014–34022. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tomasini P, Barlesi F, Mascaux C and
Greillier L: Pemetrexed for advanced stage nonsquamous non-small
cell lung cancer: Latest evidence about its extended use and
outcomes. Ther Adv Med Oncol. 8:198–208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moran DM, Trusk PB, Pry K, Paz K,
Sidransky D and Bacus SS: KRAS mutation status is associated with
enhanced dependency on folate metabolism pathways in non-small cell
lung cancer cells. Mol Cancer Ther. 13:1611–1624. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Levy B, Drilon A, Chachoua A, Seetharamu
N, Richardson S, Lucido D, Legasto A, Grossbard M and Becker D:
KRAS mutations predict sensitivity to pemetrexed-based
chemotherapy. Lung Cancer Manag. 2:275–280. 2013. View Article : Google Scholar
|
|
14
|
Gandara DR, Grimminger P, Mack PC, Lara PN
Jr, Li T, Danenberg PV and Danenberg KD: Association of epidermal
growth factor receptor activating mutations with low ERCC1 gene
expression in non-small cell lung cancer. J Thorac Oncol.
5:1933–1938. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kalikaki A, Koutsopoulos A, Hatzidaki D,
Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V
and Voutsina A: Clinical outcome of patients with non-small cell
lung cancer receiving front-line chemotherapy according to EGFR and
K-RAS mutation status. Lung Cancer. 69:110–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang S, Wang Z, Guo J, Liu J, Li C, Liu L,
Shi H, Liu L, Li H, Xie C, et al: Correlation between EGFR mutation
status and response to first-line platinum-based chemotherapy in
patients with advanced non-small cell lung cancer. Onco Targets
Ther. 7:1185–1193. 2014.PubMed/NCBI
|
|
17
|
Ren S, Chen X, Kuang P, Zheng L, Su C, Li
J, Li B, Wang Y, Liu L, Hu Q, et al: Association of EGFR mutation
or ALK rearrangement with expression of DNA repair and synthesis
genes in never-smoker women with pulmonary adenocarcinoma. Cancer.
118:5588–5594. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu CW, Wang G, Wang WL, Gao WB, Han CJ,
Gao JS, Zhang LY, Li Y, Wang L, Zhang YP, et al: Association
between EML4-ALK fusion gene and thymidylate synthase mRNA
expression in non-small cell lung cancer tissues. Exp Ther Med.
9:2151–2154. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee JO, Kim TM, Lee SH, Kim DW, Kim S,
Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, et al: Anaplastic
lymphoma kinase translocation: A predictive biomarker of pemetrexed
in patients with non-small cell lung cancer. J Thorac Oncol.
6:1474–1480. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Besse B, Olaussen KA and Soria JC: ERCC1
and RRM1: Ready for prime time? J Clin Oncol. 31:1050–1060. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Metro G, Zheng Z, Fabi A, Schell M,
Antoniani B, Mottolese M, Monteiro AN, Vici P, Rivera Lara S,
Boulware D, et al: In situ protein expression of RRM1, ERCC1, and
BRCA1 in metastatic breast cancer patients treated with
gemcitabine-based chemotherapy. Cancer Invest. 28:172–180. 2010.
View Article : Google Scholar : PubMed/NCBI
|
